TriangleNCT00517699 · OUTCOME
Percentage of Participants With Initial CR or CRu and Subsequent Disease Relapse
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- Not reported
- Unit
- Not reported
- Interval / dispersion
- Not reported
- Time frame
- Week 24
Analysis population: Due to early study termination, all efficacy data were documented by data listings only, no data analysis was performed.
Groups in this outcome
Rituximab, Cytarabine, and MTX
Participants received single doses of rituximab 750 mg/m\^2 IV at Weeks 1 through 5, and 7, 9, 11, 14, 16, 18, 20, and 22; cytarabine 2 g/m\^2 IV every 24 hours for 2 doses at Weeks 11 and 22; and single doses of MTX 8 g/m\^2 IV at Weeks 3, 5, 7, 9, 14, 16, 18, and 20.
| Group | Source count |
|---|---|
| Rituximab, Cytarabine, and MTX | 0 |
Reported measurements
No numerical measurement classes were posted for this outcome. Missing is not zero.
Complete source fields
- denoms
- counts
- group Id
- OG000
- value
- 0
- units
- Participants
- groups
- description
- Participants received single doses of rituximab 750 mg/m\^2 IV at Weeks 1 through 5, and 7, 9, 11, 14, 16, 18, 20, and 22; cytarabine 2 g/m\^2 IV every 24 hours for 2 doses at Weeks 11 and 22; and single doses of MTX 8 g/m\^2 IV at Weeks 3, 5, 7, 9, 14, 16, 18, and 20.
- id
- OG000
- title
- Rituximab, Cytarabine, and MTX
- population Description
- Due to early study termination, all efficacy data were documented by data listings only, no data analysis was performed.
- reporting Status
- POSTED
- time Frame
- Week 24
- title
- Percentage of Participants With Initial CR or CRu and Subsequent Disease Relapse
- type
- SECONDARY
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice